Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus PENICILLIN G POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus PENICILLIN G POTASSIUM.
BICILLIN L-A vs PENICILLIN G POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic